Table 1 The list of CPIs and their biological functions in different cancer types
Forms of action | CircRNA | RBP | Cancer | Biological function | Expression | year | Ref. | |
---|---|---|---|---|---|---|---|---|
a. CPIs modulating transcription | circACTN4 | YBX1 | Intrahepatic cholangiocarcinoma(ICC) | circACTN4 recruiting YBX1 to initiate FZD7 transcription to promote ICC progression | ⬆ | 2021 | ||
circNCOR1 | hnRNPL | Bladder cancer(BCa) | circNCOR1 recruits hnRNPL to lymphangiogenesis and LN metastasis of BCa in vivo | ⬆ | 2022 | |||
circMRPS35 | KAT7 | Gastric cancer(GC) | circMRPS35 recruits KAT7 to suppress GC cells progression | ⬆ | 2020 | |||
circ-HuR | CNBP | Gastric cancer | circ-HuR inhibits CNBP’s binding to HuR promoter, preventing the progression of tum | ⬆ | 2019 | |||
circRHOT1 | TIP60 | Hepatocellular carcinoma | circRHOT1 recruits TIP60 to initiate NR2F6 expression, which promotes HCC growth and metastasis | ⬆ | 2019 | |||
circ-CUX1 | EWSR1 | Neuroblastoma | circ-CUX1 interacts with EWSR1 to facilitate its interaction with MAZ, inducing tumor progression | ⬆ | 2019 | |||
circCAPRIN1 | STAT2 | Colorectal cancer | circCAPRIN1 binds STAT2 to regulate lipid metabolism and facilitates CRC tumorigenesis | ⬆ | 2023 | |||
circRNF10 | DHX15 | Breast cancer | circRNF10 interacts with DHX15 to sequester DHX15 from NF-κB p65,suppressing BC’s proliferation and migration | ⬆ | 2023 | |||
circRPPH1 | UPF1,ATF3 | Glioblastoma multiforme(GBM) | UPF1/circRPPH1/ATF3 forms a feedback loop to strengthen tumorigenesis of glioma stem cells | ⬆ | 2022 | |||
circFMN2 | HuR | Prostatic cancer(PC) | circFMN2 binds to HuR to represses KLF2 expression, which induces cell proliferation, invasion, and migration | ⬆ | 2023 | |||
has_circ_0062682 | YBX1 | Hepatocellular carcinoma | has_circ_0062682 binds to YBX1 to promote oncogenesis in HCC | ⬆ | 2022 | |||
circRPMS1 | Sam68 | Gastric carcinoma | ebv-circRPMS1 recruits Sam68 to induce METTL3 expression, resulting in cancer progression | ⬆ | 2022 | |||
circ-DONSON | NURF | Gastric cancer | circ-DONSON recruits the NURF complex to activate SOX4 transcription, and facilitates GC growth and invasion | ⬆ | 2019 | |||
has_circ_0101119 | EIF4A3 | Cervical cancer | has_circ_0101119 recruits EIF4A3 to facilitate cell process, and suppress apoptosis in CC | ⬆ | 2021 | |||
circPSD3 | HDAC1 | Hepatocellular carcinoma | circPSD3 interacts with HDAC1 to inhibit vascular invasion and metastasis in HCC | ⬆ | 2023 | |||
circ0005276 | FUS | Prostate cancer | circ0005276 interacts with FUS to promote cell proliferation, migration and EMT of PCa | ⬆ | 2019 | |||
circ_SIRT1 | EIF4A3 | Chronic myeloid leukemia(CML) | circ_SIRT1 binds to EIF4A3 and regulates transcription of ATG12,leading to lmatinib resistance in CML | ⬆ | 2024 | |||
circEHD2 | YWHAH | Renal cell carcinoma | circEHD2 interacts with YWHAH to activate transcriptional factor SOX9,which accelerates the growth of RCC | ⬆ | 2023 | |||
circIPO11 | TOP1 | Hepatocellular carcinoma | circIPO11 recruits TOP1 to promote the propagation of HCC | ⬆ | 2021 | |||
b. CPIs affecting alternative splicing | circSMARCA5 | SRSF1 | Glioblastoma | circSMARCA5 interacts with SRSF1 to induce anti-angiogenic and suppress tumor progression | ⬆ | 2019 | ||
circURI1 | hnRNPM | Gastric cancer | circURI1 inreracts with hnRNPM to promote the process of cell migration and suppressing GC metastasis | ⬆ | 2021 | |||
circRAPGEF5 | RBFOX2 | Endometrial cancer(EC) | circRAPGEF5 interacts with RBFOX2 to promote the formation of TFRC and confer ferroptosis resistance in EC cells, which facilitates rapid proliferation of EC cells | ⬆ | 2022 | |||
circCPSF6 | CPSF6 | Esophageal cell carcinoma | circCPSF6 interacts with CPSF6 to promote malignant development of ESCC | ⬆ | 2022 | |||
circRNA_100290 | EIF4A3 | Gastric cancer | circRNA_100290 binds to EIF4A3 to inhibit itself formation, leading to suppressed GC cell proliferation, migration, and invasion | ⬆ | 2021 | |||
circPLCE1 | SRSF2 | Colorectal cancer | circPLCE1 binds to SRSF2 protein to repress PLCE1 pre-RNA splicing,which up-regulates CRC | ⬆ | 2021 | |||
circPDIA4 | DHX9,ERK1/2 | Gastric cancer | cytoplasmic circPDIA4 binds to ERK1/2, while circPDIA4 interacts with DHX9 as a decoy in the nucleus, which promotes GC progression | ⬆ | 2023 | |||
c. CPIs affecting translation | circMYBL2 | cpSF6 | AML | circMYBL2 recruits PTBP1 to enhance FLT3 kinase expression and promote FLT3-ITD AML progression | ⬆ | 2019 | ||
has_circ_0068631 | EIF4A3 | Breast cancer | EIF4A3 binds to has_circ_0068631 and c-Myc mRNA to promote BC progression | ⬆ | 2021 | |||
circDLC1 | HuR | Hepatocellular carcinoma(HCC) | circDLC1 interacts with HuR to inhibit MMP1-mediated HCC progression | ⬆ | 2021 | |||
circ0008399 | WTAP | Bladder cancer | circ0008399 unites WTAP to formate the WTAP/METTL3/METTL14 complex to inhibit apoptosis of BCa cells and reduce cisplatin sensitivity in Bca | ⬆ | 2021 | |||
circLPAR1 | eIF3h | Colorectal cancer(CRC) | exosomal circLPAR1 binds with eIF3h to suppress tumor growth | ⬆ | 2022 | |||
circARHGAP29 | EIF4A3,IGF2BP2 | Prostate cancer(PC) | circARHGAP29 binds with EIF4A3 and IGF2BP2 to facilitate docetaxel resistance and glycolysis in PC | ⬆ | 2022 | |||
circMYH9 | hnRNPA2B1 | Colorectal cancer(CRC) | circMYH9 recruits hnRNPA2B1 and destabilizes the pre-mRNA of p53,inducing tumor growth | ⬆ | 2021 | |||
circITGB6 | IGF2BP2 | Ovarian cancer(OC) | circITGB6 interacts with both IGF2BP2 and FGF9 mRNA, inducing cisplatin resistance in OC | ⬆ | 2022 | |||
circ-TNPO3 | IGF2BP2 | Clear cell renal cell carcinoma(ccRCC) | circ-TNPO3 binds to IGF2BP2 and destabilizes SERPINH1 mRNA, suppressing proliferation and migration of ccRCC cells | ⬆ | 2022 | |||
circPTPRA | IGF2BP1 | Bladder cancer | circPTPRA interacts with IGF2BP1 to abolish the promotion of BC cells | ⬆ | 2021 | |||
circTICRR | HuR | Cervical cancer(CC) | circTICRR interacts with HuR to stabilize GLUD1 mRNA and inhibits CC cells’ autophagy | ⬆ | 2022 | |||
has_circ_0005358 | PTBP1 | Cervical cancer | has_circ_0005358 sequesters PTBP1 form stabilizing CDCP1 mRNA,suppressing cancer metastasis | ⬆ | 2022 | |||
circDCUN1D4 | HuR | Lung adenocarcinoma | circDCUN1D4 facilitates the interaction between HuR protein and TXNIP mRNA to suppress tumor metastasis and glycolysis | ⬆ | 2021 | |||
circPBX3 | IGF2BP2 | Ovarian cancer | circPBX3 interacts with IGF2BP2 to promote cisplatin resistance of OC cells | ⬆ | 2022 | |||
circIPO7 | caprin-1 | Gastric cancer | circIPO7 binds to caprin-1 to block the caprin-1-G3BP1 interaction, resulting in suppressing GC cell proliferation | ⬆ | 2023 | |||
circUHRF2 | IGF2BP1 | Colorectal cancer | circUHRF2 promotes the interaction between IGF2BP1 and DDX27 mRNA, which induces CRC stemness and metastasis | ⬆ | 2023 | |||
circXRCC5 | IGF2BP2 | Glioma | circXRCC5 binds to IGF2BP2 to maintain mRNA stability of CLC3,which ultimately accelerate glioma growth | ⬆ | 2023 | |||
circITGB6 | IGF2BP3 | Colorectal cancer | circITGB6 interacts with IGF2BP3 and enhances the PDPN mRNA’s stability, which promotes the EMT process | ⬆ | 2023 | |||
circPCNX | AUF1 | Cervical cancer | circPCNX sequesters AUF1 from p21 mRNA to inhibit proliferation in HeLa cells | ⬆ | 2021 | |||
circASPH | IGF2BP2 | Colorectal cancer | circASPH interacts with IGF2BP2 to stabilize its protein level to accelerate CRC progression | ⬆ | 2023 | |||
circREOS | HuR | Osteosarcoma(OS) | circREOS sequesters HuR from MYC mRNA to inhibit OS | ⬆ | 2023 | |||
circABCC4 | IGF2BP2 | Prostate cancer | circABCC4 recruits IGF2BP2 to promote stemness and metastasis of prostate cancer | ⬆ | 2023 | |||
circSETD3 | FXR1 | Non-small lung cancer | circSETD3 interacts with FXR1 and facilitates its binding to ECT2,which inhibits cellular apoptosis | ⬆ | 2023 | |||
hsa_circ_0006232 | FUS,EZH2 | Laryngeal squamous cell carcinoma | FUS interacts with hsa_circ_0006232 and EZH2 and promotes the stabilization of EZH2, which promotes the biological functions of LSCC cells | ⬆ | 2021 | |||
circRABL2B | YBX1 | Lung cancer | circRABL2B interacts with YBX1 to suppress lung cancer progression | ⬆ | 2023 | |||
hsa_circ_0036200(Cpkm) | IGF2BP2 | Intrahepatic cholangiocarcinoma(ICC) | cPKM binds to IGF2BP2 to enhance ICC’s progression and resistance to paclitaxel, leading to vascular collapse | ⬆ | 2023 | |||
circXPO1 | IGF2BP1 | Lung adenocarcinoma | circXPO1 interacts with IGF2BP1 to enhance the stability of CTNNB1 mRNA to promote LUAD progression | ⬆ | 2020 | |||
circKIF4A | EIF4A3 | Triple-negative breast cancer(TNBC) | circKIF4A binds to EIF4A3 to stabilize SDC1 mRNA, resulting in promoting TNBC progression | ⬆ | 2023 | |||
circARHGAP5 | AUF1 | Cervival squamous cell carcinoma(CSCC) | circARHGAP5 sequesters AUF1 from BIM mRNA, which induces cisplatin resistance in CSCC | ⬆ | 2023 | |||
hsa_circ_0074854 | HuR | Hepatocellular carcinoma | hsa_circ_0074854 knockdown interacts with HuR to reduce its stability, leading to inhibiting HCC cells’ migration and invasion | ⬆ | 2021 | |||
circ-TNPO3 | IGF2BP3 | Gastric cancer | circ-TNPO3 competes with IGF2BP3 to disrupt its ability to stabilize MYC mRNA, resulting in the inhibition of GC cells | ⬆ | 2021 | |||
circ-MMP9 | AUF1 | Oral squamous cell carcinoma | circ-MMP9 binds to AUF1 to increase MMP9 mRNA’s stability, which facilitates OSCC metastasis | ⬆ | 2019 | |||
circ-0075804 | HNRNPK | Retinoblastoma(RB) | circ-0075804 interacts with HNRNPK to increase E2F3 mRNA stability, which promotes RB cells’ proliferation | ⬆ | 2020 | |||
circRBM33 | FMR1 | Prostate cancer | m6A-modified circRBM33 interacts with FMR1 and sustain the mRNA stability of PDHA1,which promotes PCa progression | ⬆ | 2023 | |||
circNSUN2 | IGF2BP2 | Colorectal carcinoma | circNSUN2 forms a circNSUN2/IGF2BP2/HMGA2 ternary complex to promote CRC metastasis | ⬆ | 2019 | |||
d. CPIs affecting subcellular localization | circIPO7 | YBX1 | Nasopharyngeal carcinoma(NPC) | circIPO7 binds to YBX1 protein and facilitates its phosphorylation to promote NPC metastasis and cisplatin chemoresistance | ⬆ | 2022 | ||
circSPARC | FUS | Colorectal cancer | circSPARC recruits FUS and facilitates STAT3’s nuclear translocation, which promotes CRC cell migration and proliferation | ⬆ | 2021 | |||
has_circ_0005050 | ILF3 | Arsenic carcinoma | has_circ_0005050 interacts with ILF3 to facilitate its translocation to cytoplasm, leading to cell apoptosis and proliferation | ⬆ | 2022 | |||
circTBC1D14 | FUS | Triple-negative breast cancer | circTBC1D14 can promote the interaction between FUS and LAMP1,promoting tumor progression in TNBC | ⬆ | 2023 | |||
circHIF1A | NFIB,FUS | Triple-negative breast cancer | circHIF1A/NFIB/FUS forms a positive feedback loop to promote TNBC growth and metastasis | ⬆ | 2021 | |||
hsa_circ_0067842 | HuR | Breast cancer | hsa_circ_0067842 interacts with HuR to promote the migration and invasion of BC cells | ⬆ | 2023 | |||
circ-ABCC1 | β-catenin | Colorectal cancer | circ-ABCC1 interacts with β-catenin to facilitate CRC progression and metastasis | ⬆ | 2020 | |||
circ_GRHPR | PCBP2 | Non-small cell lung cancer(NSCLC) | circ_GRHPR interacts with PCBP2 to promote NSCLC proliferation and invasion | ⬆ | 2021 | |||
circIMMP2L | CtBP1 | Esophageal squamous cell carcinoma | circIMMP2L interacts with CtBP1 and facilitates its nuclear retention in the nucleus, which promotes ESCC’s progression | ⬆ | 2021 | |||
circEML4 | ALKBH5 | Non-small cell lung cancers | circEML4 interacts with ALKBH5 to reduce its distribution in the nucleus, resulting in promoting the NSCLC progression | ⬆ | 2023 | |||
circTET2 | HNRNPC | Chronic lymphocytic leukemia(CLL) | m6A-modified circTET2 interacts with HNRNPC and restricts its transportation from the nucleus to the cytoplasm, which promotes the proliferation of CLL | ⬆ | 2023 | |||
circAGO2 | HuR | - | circAGO2 facilitates HuR’s translocation from the nucleus to cytoplasm, leading to the promotion of tumorigenesis | ⬆ | 2019 | |||
e. CPIs affecting PTM | circRNA-CREIT | DHX9 | Triple-negative breast cancer(TNBC) | circRNA-CREIT interacts with DHX9 to induce a lower expression and worse prognosis of patients | ⬆ | 2022 | ||
phosphorylation | circEIF3I | SMAD3,AP2A1 | Pancreatic ductal adenocarcinoma(PDAC) | circEIF3I binds both SMAD3 and AP2A1 and promote PDAC progression | ⬆ | 2023 | ||
circNFIB | MEK1 | Intrahepatic cholangiocarcinoma | circNFIB binds to MEK1 to inhibit ICC growth and metastasis | ⬇ | 2022 | |||
circLIFR | MSH2 | Bladder cancer | circLIFR interacts with MSH2 to mediate cisplatin(CDDP) sensitivity in BCa cells | ⬆ | 2021 | |||
circCYP24A1 | PKM2 | Esophageal cell carcinoma(ESCC) | circCYP24A1 interacts with PKM2 to increase CCL5 secretion, which promotes the proliferation ability and tumor growth | ⬆ | 2022 | |||
circGNG7 | HSP27 | Head and neck squamous cell carcinoma(HNSCC) | circGNG7 binds to HSP27 to hinder its phosphorylation, which inhibits tumor cell proliferation, colony formation | ⬇ | 2021 | |||
circPTK2 | vimentin | Colorectal cancer | circPTK2 binds to vimentin protein to promote EMT of CRC cells | ⬆ | 2020 | |||
circGSK3β | GSK3β | Esophageal squamous cell carcinoma(ESCC) | circGSK3β sequesters GSK3β from β-catenin to promote ESCC cell metastasis | ⬆ | 2019 | |||
circ-GLI1 | p70S6K2 | Melanoma | circ-GLI1 interacts with p70S6K2 to promote metastasis in melanoma | ⬆ | 2020 | |||
ubiqutination | circPDK1 | UBE20,B1N1 | Pancreatic cancer(PC) | circPDK1 enhances the interaction between UBE20 and B1N1 to induce PC proliferation, migration,and glycolysis | ⬆ | 2022 | ||
circPOLR2A | UBE3C,PEBP1 | Clear cell renal cell carcinoma(cRCC) | circPOLR2A interacts with both UBE3C and PEBP1 proteins to accelerate the proliferation, migration and angiogenesis of cRCC cells | ⬆ | 2022 | |||
circNDUFB2 | TRIM25,IGF2BPs | Non-small cell lung cancer | circNDUFB2 enhances the interaction between TRIM25 and IGF2BPs to promote NSCLC progression and metastasis | ⬇ | 2021 | |||
circARHGAP10 | TRIM25,MAT2A | Bladder cancer | circARHGAP10 enhances the interaction between TRIM25 and MAT2A to induce cisplatin resistance in BCa cells | ⬆ | 2023 | |||
circPFKFB4 | CRL4DDB2 E3 ubiquitin ligase | Breast cancer | circPFKFB4 interacts with CRL4DDB2 E3 ubiquitin ligase to promote the proliferation of BC cells | ⬆ | 2022 | |||
CircCDR1as | SRSF1 | Lung cancer | circCDR1as binds to SRSF1 to mediate PM2.5-induced lung cancer progression. | ⬆ | 2023 | |||
circSCL38A1 | ILF3 | Bladder cancer | circSCL38A1 could interact with and stabilize ILF3 to promote BCa cell invasion and lung metastasis | ⬆ | 2023 | |||
circMTCL1 | C1QBP | Laryngeal squamous cell carcinoma(LSCC) | circMTCL1 recruits C1QBP protein to accelerate its translation and promote tumor cell proliferation invasion and migration | ⬆ | 2022 | |||
circCDYL2 | GRB7,FAK | Breast cancer | circCDYL2 binds both GRB7 and FAK protein to promote drug resistance of HER2 BC cells | ⬇ | 2022 | |||
circRNA-SORE | YBX1 | Hepatocellular carcinoma | circRNA-SORE binds to YBX1 and blocks its degradation, inducing sorafenib resistance in HCC | ⬇ | 2020 | |||
circNEIL3 | YBX1 | Colorectal carcinoma | circNEIL3 interacts with YBX1 and promotes its degradation to inhibit tumor metastasis | ⬇ | 2023 | |||
circWSB1 | USP10 | Breast cancer | hypoxia-induced circWSB1 competitively binds to USP10,resulting in degradation of p53 and BC progression | ⬆ | 2022 | |||
circSKA3 | SLUG | Colorectal cancer | circSKA3 binds to SLUG to promote EMT to accelerate CRC metastasis | ⬆ | 2023 | |||
circRNA-SFMBT2 | RNF181,ERα | Breast cancer | circRNA-SFMBT2 recruits RNF181 to ERα to enhance ERα stability, leading to tumor progression | ⬆ | 2023 | |||
circCLNS1A | LARP1 | Hepatoblastoma(HB) | O-GlcNAcylation of LARP1 enhances its binding to circCLNS1A and facilitates HB progression | ⬆ | 2023 | |||
circNFATC3 | IGF2BP3 | Gastric cancer | circNFATC3 binds to IGF2BP3 and restricts its ubiquitination to promote the proliferation of GC | ⬆ | 2023 | |||
circSKA3 | β-catenin | Colorectal cancer | circSKA3 binds to β-catenin and protects them from ubiquitinated degradation, which promotes CRC progression | ⬆ | 2023 | |||
neddylation | circAFF2 | CAND1,Cullin1 | Colorectal cancer | circAFF2 binds CAND1, enhancing its interaction with Cullin1 and inhibiting neddylation, impacting CRC radiosensitivity | ⬆ | 2023 | ||
SUMOylation | circTLCD4-RWDD3 | hnRNPA2B1 | Non-small cell lung cancer | circTLCD4-RWDD3 interacts and induces hnRNPA2B1 SUMOylation to promote lymphatic metastasis of NSCLC | ⬆ | 2023 | ||
glycosylation | circSPIRE1 | ELAVL1,mRNA | Renal cell carcinoma(RCC) | circSPIRE1 binds both ELAVL1 and mRNA to suppress metastasis of RCC | ⬇ | 2023 | ||
acetylation | circPTPN22 | STAT3 | Pancreatic cancer | circPTPN22 promotes STAT3 acetylation via inhibiting the interaction between STAT3 and SIRT1,which attenuates PC immune microenvironment | ⬆ | 2023 | ||
lactylation | circXRN2 | LAST1 | Bladder cancer | circXRN2 interacts with SPOP to inhibit the proliferation and migration of tumor cells | ⬇ | 2023 | ||
f. The form that has not been elaborated in detail | circRNA-101093 | FABP3 | Lung adenocarcinoma(LUAD) | exosomal cir93 interacts with and increases FABP3, reducing llipid peroxidation and desensitized LUAD cells to ferroptosis | ⬆ | 2022 | ||
circRNA_102231 | IRTKS | Gastric cancer | circRNA_102231 binds to and increases IRTKS stability, leading to GC progression | ⬆ | 2021 | |||
circEXOC6B | RRAGB | Colorectal cancer | circEXOC6B binds to RRAGB and suppresses the Mtorc1 pathway and HIF1A level, which inhibits growth and increases apoptosis of CRC cells | ⬇ | 2022 | |||
circCDYL2 | Ezrin | Colorectal cancer | circCDYL2 interacts with Ezrin and increases its protein levels, which induces CRC cell migration in vitro | ⬆ | 2021 | |||
Circ SMARCA5 | SND1 | Cervical cancer | circ SMARCA5 interacts with SND1 to inhibit SND1’s binding to YWHAB, and suppresses CC metastasis | ⬇ | 2021 | |||
circPFKP | IMPDH2,hnRNPF | Prostate cancer | circPFKP interacts with IMPDH2 to promote the biogenesis of guanine nucleotides and facilitate PCa cells’proliferation | ⬆ | 2022 | |||
circHIPK3 | VCP | Bladder cancer | circHIPK3 interacts with VCP and blocks VCP binding to the Beclin1 complex, which suppresses autophagy in BC cells | ⬇ | 2023 |